Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab and Talquetamab in Frail Patients With Newly Diagnosed Multiple Myeloma
NCT07107529Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Apr 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of teclistamab, talquetamab in multiple myeloma (MM). Started Dec 2025; status: recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07107529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107529.